Status and phase
Conditions
Treatments
About
A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)
Full description
The study aims to evaluate and quantify the effect of pyridostigmine on symptoms and muscle strength in newly-diagnosed patients and patients on stable medication.
Pyridostigmine treatment is initiated in the vast majority of MG patients. No studies have quantified the effect in a randomized trial, and no studies have examined the potential difference in effect in newly diagnosed patients as compared to patients on stable, antimyasthenic medications.
The study will investigate the effect in two groups
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
De-novo MG Eligibility Criteria
Chronic MG Eligibility Criteria
Primary purpose
Allocation
Interventional model
Masking
44 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Jan LS Thomsen, MD; Henning Andersen, MD PhD DMSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal